Summary
Amgen Inc. (AMGN) filed an 8-K on May 11, 2017, to report the significant issuance and sale of a substantial amount of debt. The company raised approximately $3.48 billion in net proceeds through the sale of various senior notes, including both floating rate and fixed rate tranches with maturities ranging from 2019 to 2022. This debt offering is a key event for investors as it signals Amgen's financing strategy and potentially its plans for future investments, acquisitions, or debt management. The detailed terms of the notes, including interest rates and maturity dates, provide insight into the company's cost of capital and its approach to managing its balance sheet. Investors should note the total debt raised and the diverse range of maturities, which can impact future financial flexibility and leverage.
Key Highlights
- 1Amgen Inc. successfully issued and sold a total of approximately $3.48 billion in net proceeds from various senior notes.
- 2The debt issuance includes $600 million in Senior Floating Rate Notes due 2019 and 2020, with interest rates tied to three-month LIBOR plus a spread.
- 3Additionally, $3.6 billion in fixed rate Senior Notes were issued with coupon rates ranging from 1.900% to 2.650% and maturities in 2019, 2020, and 2022.
- 4The notes are registered under an effective Form S-3 registration statement, indicating they were issued as part of a shelf registration.
- 5In the event of a change of control triggering an event, noteholders have the option to require Amgen to repurchase their notes at 101% of the principal amount plus accrued interest.
- 6The newly issued notes rank equally with other senior unsecured indebtedness of Amgen.
- 7The company also filed its computation of the ratio of earnings to fixed charges for the relevant periods.